Top

Applied Health Economics and Health Policy

Published in:

31-01-2023 | Systematic Review

A Systematic Review of Health Economic Evaluations and Budget Impact Analyses to Inform Healthcare Decision-Making in Central America

Authors: Carlos Rojas-Roque, Alfredo Palacios

Published in: Applied Health Economics and Health Policy | Issue 3/2023

Abstract

Background

Little is known about the quality, quantity and disease areas analysed by health economic research that inform healthcare decision-making in Central America. This study aimed to review the existing health economic evaluations (HEEs) and budget impact analyses (BIAs) evidence in Central America based on scope and reporting quality.

Methods

HEEs and BIAs published from 2000 to April 2021 were searched in five electronic databases: PubMed, Embase, LILACS (Latin American and Caribbean Health Science Literature), EconLIT and OVID Global Health. Two reviewers assessed titles, abstracts and full texts of studies for eligibility. The quality appraisal for the reporting was based on La Torre and colleagues' version of the Drummond checklist and the ISPOR good practices for BIA. For each country, we correlated the number of studies by disease area with their respective burden of disease to identify under-researched health areas.

Results

102 publications were eligible for this review. Ninety-four publications reported a HEE, six publications reported a BIA, and two studies reported both a HEE and a BIA. Costa Rica had the highest number of publications (n = 28, 27.5%), followed by Guatemala (n = 25, 24.5%). Cancer and respiratory infections were the most common types of disease studied. Diabetes mellitus, chronic kidney diseases, and mental disorders were under-researched relative to their disease burden in most of the countries. The overall mean quality reporting score for HEE and BIA studies were 71/119 points (60%) and 7/10 points (70%), respectively; however, these assessments were made on different scales.

Conclusion

In Central America, health economic research is sparse and is considered as suboptimal quality for reporting. The findings reported information useful to other low- and middle-income countries with similar advances in the application of economics to promote health policy decision-making.

Available only for authorised users

Atun R, de Andrade LOM, Almeida G, Cotlear D, Dmytraczenko T, Frenz P, et al. Health-system reform and universal health coverage in Latin America. Lancet [Internet]. 2015;385:1230–47. https://doi.org/10.1016/S0140-6736(14)61646-9.CrossRefPubMed

The World Health Organization. Constitution of the World Health Organization [Internet]. 1948. Acessed 2022 Jan 13. https://www.who.int/about/governance/constitution.

Ottersen T, Norheim OF, World Health Organization Consultative Group on Equity and Universal Health Coverage. Making fair choices on the path to universal health coverage. Bull World Health Organ [Internet]. 2014;92:389. https://doi.org/10.2471/BLT.14.139139.

García-Guerrero VM, Masferrer C, Giorguli-Saucedo SE. [Migration and aging in countries of origin and destination. The case of North America and Central America]. RELAP [Internet]. 2019;13:36–53. [cited 2022 Dec 10] http://revistarelap.org/index.php/relap/article/view/59. Accessed 04 Dec 2022.

Duda-Nyczak M. Demographic transition and achieving the SDGs in Latin America and the Caribbean: a regional overview of the National Transfer Accounts [Internet]. Santiago: Economic Commission for Latin America and the Caribbean (ECLAC); 2021. Report No.: 135. https://repositorio.cepal.org/bitstream/handle/11362/47418/3/S2100745_en.pdf.

Marinho FM, Soliz P, Gawryszewski V, Gerger A. Epidemiological transition in the Americas: changes and inequalities. Lancet [Internet]. Elsevier; 2013;381:S89. http://www.thelancet.com/article/S0140673613613434/abstract. Accessed 10 Dec 2022.

The World Bank. World Development Indicators [Internet]. World Development Indicators. 2019. https://databank.worldbank.org/source/world-development-indicators. Accessed 11 Jun 2022.

Bowser DM, Mahal A. Guatemala: the economic burden of illness and health system implications. Health Policy [Internet]. 2011;100:159–66. https://doi.org/10.1016/j.healthpol.2010.11.011.CrossRefPubMed

Becerril-Montekio, López-Dávila. Sistema de salud de Guatemala. Salud pública Méx [Internet]. http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0036-36342011000800015&lng=en&nrm=iso.

10.

Bermúdez-Madriz JL, del Sáenz MR, Muiser J, Acosta M. The health system of Honduras. Salud Publica Mex [Internet]. 2011;53(Suppl 2):s209–19.PubMed

11.

Vargas-Palacios E, Pineda R, Galán-Rodas E. The politicised and crumbling Nicaraguan health system [Internet]. Lancet. 2018. https://doi.org/10.1016/S0140-6736(18)32990-8.CrossRefPubMed

12.

Muiser, Sáenz, Bermúdez. Sistema de salud de Nicaragua. Salud pública Méx [Internet]. http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0036-36342011000800018&lng=es&nrm=iso.

13.

Acosta M, del Sáenz MR, Gutiérrez B, Bermúdez JL. The health system of El Salvador. Salud Publica Mex [Internet]. 2011;53(Suppl 2):s188–96.PubMed

14.

Romero LI, Quental C. The Panamanian health research system: a baseline analysis for the construction of a new phase. Health Res Policy Syst [Internet]. 2013;11:33. https://doi.org/10.1186/1478-4505-11-33.CrossRefPubMedPubMedCentral

15.

Oecd, Organisation for Economic Co-operation and Development. OECD Reviews of Health Systems: Costa Rica 2017 [Internet]. OECD; 2017. https://play.google.com/store/books/details?id=DaG7swEACAAJ.

16.

Sáenz, Acosta, Muiser, Bermúdez. Sistema de salud de Costa Rica. Salud pública Méx [Internet]. Available from: http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0036-36342011000800011&lng=en&nrm=iso.

17.

Health Technology Assessment Network of the Americas (RedETSA) [Internet]. RedETSA. 2011 [cited 2022 Feb 14]. https://redetsa.bvsalud.org/en/.

18.

Rosselli D, Quirland-Lazo C, Csanádi M, Ruiz de Castilla EM, González NC, Valdés J, et al. HTA implementation in Latin American countries: comparison of current and preferred status. Value Health Reg Issues [Internet]. 2017;14:20–7. https://doi.org/10.1016/j.vhri.2017.02.004.

19.

Pichon-Riviere A, Soto NC, Augustovski FA, García Martí S, Sampietro-Colom L. Health technology assessment for decision making in Latin America: good practice principles. Int J Technol Assess Health Care [Internet]. 2018;34:241–7. https://doi.org/10.1017/S0266462318000326.CrossRefPubMed

20.

Anderson R. Systematic reviews of economic evaluations: utility or futility? Health Econ [Internet]. 2010;19:350–64. https://doi.org/10.1002/hec.1486.CrossRefPubMed

21.

Pitt C, Goodman C, Hanson K. Economic evaluation in global perspective: a bibliometric analysis of the recent literature. Health Econ [Internet]. 2016;25(Suppl 1):9–28. https://doi.org/10.1002/hec.3305.CrossRefPubMedPubMedCentral

22.

Lee K-S, Brouwer WBF, Lee S-I, Koo H-W. Introducing economic evaluation as a policy tool in Korea: will decision makers get quality information? : a critical review of published Korean economic evaluations. Pharmacoeconomics [Internet]. 2005;23:709–21. https://doi.org/10.2165/00019053-200523070-00005.CrossRefPubMed

23.

Teerawattananon Y, Russell S, Mugford M. A systematic review of economic evaluation literature in Thailand: are the data good enough to be used by policy-makers? Pharmacoeconomics [Internet]. 2007;25:467–79. https://doi.org/10.2165/00019053-200725060-00003.CrossRefPubMed

24.

Gavaza P, Rascati K, Brown C, Lawson K, Mann T. The state of health economic and pharmacoeconomic evaluation research in Zimbabwe: a review. Curr Ther Res Clin Exp [Internet]. 2008;69:268–85. https://doi.org/10.1016/j.curtheres.2008.06.005.CrossRefPubMedPubMedCentral

25.

Gavaza P, Rascati KL, Oladapo AO, Khoza S. The state of health economic evaluation research in Nigeria: a systematic review. Pharmacoeconomics [Internet]. 2010;28:539–53. https://doi.org/10.2165/11536170-000000000-00000.CrossRefPubMed

26.

Hoque ME, Khan JA, Hossain SS, Gazi R, Rashid H-A, Koehlmoos TP, et al. A systematic review of economic evaluations of health and health-related interventions in Bangladesh. Cost Eff Resour Alloc [Internet]. 2011;9:12. https://doi.org/10.1186/1478-7547-9-12.CrossRefPubMedPubMedCentral

27.

Gavaza P, Rascati KL, Oladapo AO, Khoza S. The state of health economic research in South Africa: a systematic review. Pharmacoeconomics [Internet]. 2012;30:925–40. https://doi.org/10.2165/11589450-000000000-00000.CrossRefPubMed

28.

Al-Aqeel SA. State of health economic evaluation research in Saudi Arabia: a review. Clinicoecon Outcomes Res [Internet]. 2012;4:177–84. https://doi.org/10.2147/CEOR.S31087.CrossRefPubMedPubMedCentral

29.

Atehortúa S, Ceballos M, Gaviria CF, Mejía A. Quality assessment of economic evaluations in health care in Colombia: a systematic review. Biomedica [Internet]. 2013;33:615–30. https://doi.org/10.7705/biomedica.v33i4.1536.CrossRefPubMed

30.

Tran BX, Nong VM, Maher RM, Nguyen PK, Luu HN. A systematic review of scope and quality of health economic evaluation studies in Vietnam. PLoS One [Internet]. 2014;9:e103825. https://doi.org/10.1371/journal.pone.0103825.CrossRefPubMed

31.

Prinja S, Chauhan AS, Angell B, Gupta I, Jan S. A systematic review of the state of economic evaluation for health care in India. Appl Health Econ Health Policy [Internet]. 2015;13:595–613. https://doi.org/10.1007/s40258-015-0201-6.CrossRefPubMed

32.

Decimoni TC, Leandro R, Rozman LM, Craig D, Iglesias CP, Novaes HMD, et al. Systematic review of health economic evaluation studies developed in Brazil from 1980 to 2013. Front Public Health [Internet]. 2018;6:52. https://doi.org/10.3389/fpubh.2018.00052.CrossRefPubMedPubMedCentral

33.

Faleiros DR, Álvares J, Almeida AM, de Araújo VE, Andrade EIG, Godman BB, et al. Budget impact analysis of medicines: updated systematic review and implications. Expert Rev Pharmacoecon Outcomes Res [Internet]. 2016;16:257–66. https://doi.org/10.1586/14737167.2016.1159958.CrossRefPubMed

34.

van de Vooren K, Duranti S, Curto A, Garattini L. A critical systematic review of budget impact analyses on drugs in the EU countries. Appl Health Econ Health Policy [Internet]. 2014;12:33–40. https://doi.org/10.1007/s40258-013-0064-7.CrossRefPubMed

35.

Orlewska E, Gulácsi L. Budget-impact analyses: a critical review of published studies. Pharmacoeconomics [Internet]. 2009;27:807–27. https://doi.org/10.2165/11313770-000000000-00000.CrossRefPubMed

36.

Abdallah K, Huys I, Claes K, Simoens S. Methodological quality assessment of budget impact analyses for orphan drugs: a systematic review. Front Pharmacol [Internet]. 2021;12:630949. https://doi.org/10.3389/fphar.2021.630949.CrossRefPubMedPubMedCentral

37.

Foroutan N, Tarride J-E, Xie F, Levine M. A methodological review of national and transnational pharmaceutical budget impact analysis guidelines for new drug submissions. Clinicoecon Outcomes Res [Internet]. 2018;10:821–54. https://doi.org/10.2147/CEOR.S178825.CrossRefPubMedPubMedCentral

38.

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ [Internet]. 2021;372: n71. https://doi.org/10.1136/bmj.n71.CrossRefPubMedPubMedCentral

39.

Covidence Systematic Review Software [Internet]. Melbourne, Australia: Veritas Health Innovation; http://www.covidence.org.

40.

Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane Handbook for Systematic Reviews of Interventions [Internet]. John Wiley & Sons, Incorporated; 2019. https://training.cochrane.org/handbook.

41.

Han L, Zhang X, Fu W-Q, Sun C-Y, Zhao X-M, Zhou L-R, et al. A systematic review of the budget impact analyses for antitumor drugs of lung cancer. Cost Eff Resour Alloc [Internet]. 2020;18:55. https://doi.org/10.1186/s12962-020-00253-5.CrossRefPubMedPubMedCentral

42.

Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ [Internet]. 1996;313:275–83. https://doi.org/10.1136/bmj.313.7052.275.

43.

La Torre G, Nicolotti N, de Waure C, Ricciardi W. Development of a weighted scale to assess the quality of cost-effectiveness studies and an application to the economic evaluations of tetravalent HPV vaccine. J Public Health [Internet]. 2011;19:103–11. https://doi.org/10.1007/s10389-010-0377-z.CrossRef

44.

Mauskopf JA, Sullivan SD, Annemans L, Caro J, Mullins CD, Nuijten M, et al. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices—budget impact analysis. Value Health [Internet]. 2007;10:336–47. https://doi.org/10.1111/j.1524-4733.2007.00187.x.CrossRefPubMed

45.

Mauskopf J, Earnshaw SR, Brogan A, Wolowacz S, Brodtkorb T-H. Budget-impact analysis of health care interventions: a practical guide [Internet]. Berlin: Springer; 2017. https://doi.org/10.1007/978-3-319-50482-7.

46.

GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet [Internet]. 2020;396:1204–22. https://doi.org/10.1016/S0140-6736(20)30925-9.

47.

Meltzer MI. Introduction to health economics for physicians. Lancet [Internet]. 2001;358:993–8. https://doi.org/10.1016/S0140-6736(01)06107-4.CrossRefPubMed

48.

Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes [Internet]. Oxford University Press; 2015. https://play.google.com/store/books/details?id=yzZSCwAAQBAJ.

49.

Hernandez-Alvarez C, Arosteguí J, Suazo-Laguna H, Reyes RM, Coloma J, Harris E, et al. Community cost-benefit discussions that launched the Camino Verde intervention in Nicaragua. BMC Public Health [Internet]. 2017;17:396. https://doi.org/10.1186/s12889-017-4292-x.CrossRefPubMedPubMedCentral

50.

Koontz SL, Molina de Perez O, Leon K, Foster-Rosales A. Treating incomplete abortion in El Salvador: cost savings with manual vacuum aspiration. Contraception [Internet]. 2003;68:345–51. https://doi.org/10.1016/s0010-7824(03)00162-8.

51.

Walwyn L, Janusz CB, Clark AD, Prieto E, Waight E, Largaespada N. Cost-effectiveness of HPV vaccination in Belize. Vaccine [Internet]. 2015;33 Suppl 1:A174–81. https://doi.org/10.1016/j.vaccine.2014.12.042.

52.

F, Carlos. Cost-effectiveness of rituximab versus alternative anti-tumor necrosis factor (TNF) therapy after previous failure of one anti-TNF agent for treatment of rheumatoid arthritis in Costa Rica. Value in Health Regional Issues [Internet]. The Professional Society for Health Economics and Outcomes Research (ISPOR); 2010 [cited 2021 Jun 3];13:A309. https://www.ispor.org/publications/journals/value-in-health/abstract/Volume-13--Issue-7/PMS39-COST-EFFECTIVENESS-OF-RITUXIMAB-VERSUS-ALTERNATIVE-ANTI-TUMOR-NECROSIS-FACTOR-(TNF)-THERAPY-AFTER-PREVIOUS-FAILURE-OF-ONE-ANTI-TNF-AGENT-FOR-TREATMENT-OF-RHEUMATOID-ARTHRITIS-IN-COSTA-RICA.

53.

Garita, M, Solano, A, Cuesta G, Mould J. A Cost-Effectiveness Analysis of Linezolid Versus Vancomycin for Ventilator-Associated Pneumonia Patients in Costa Rica. Value in Health Regional Issues [Internet]. The Professional Society for Health Economics and Outcomes Research (ISPOR); 2013 [cited 2021 Jun 3];16:A353–4. https://www.ispor.org/publications/journals/value-in-health/abstract/Volume-16--Issue-7/A-Cost-Effectiveness-Analysis-of-Linezolid-Versus-Vancomycin-for-Ventilator-Associated-Pneumonia-Patients-in-Costa-Rica.

54.

Lutz MA, Bogantes JP, Cuesta G, Saenz R. Cost-Effectiveness Analysis Of Etanercept Versus Available Anti-Tnf And Il-6 Blockers For Treating Rheumatoid Arthritis In Costa Rica. Value Health [Internet]. Elsevier; 2013 [cited 2021 Aug 30];16:A224. http://www.valueinhealthjournal.com/article/S1098301513012084/abstract.

55.

Roberts CS, McGarry L, Gilmore K, Lutz MA, Strutton DR. Economic Assessment Of High-Risk Versus Universal Pediatric PCV13 Vaccination Programs In Costa Rica. Value Health [Internet]. Elsevier; 2013 [cited 2021 Aug 30];16:A88. http://www.valueinhealthjournal.com/article/S1098301513004798/abstract.

56.

Rosado-Buzzo A, Garcia-Mollinedo L, Luna-Casas G, Lutz MA, Bogantes JP, Sobrino JM, et al. Economic evaluation of apixaban for atrial fibrillation in Costa Rica. Value Health [Internet]. Elsevier; 2013 [cited 2021 Aug 30];16:A286. http://www.valueinhealthjournal.com/article/S1098301513015568/abstract.

57.

Desanvicente-Celis Z, Obando CA, Chaves M, Gonzalez L, Muschett D. Cost-effectiveness analysis of bendamustine-rituximab treatment compared with fludarabine-rituximab treatment, in patients with indolent non-Hodgkin’s lymphoma in Costa Rica. Value Health [Internet]. Elsevier; 2014 [cited 2021 Aug 31];17:A85. http://www.valueinhealthjournal.com/article/S1098301514005488/abstract.

58.

Obando CA, Desanvicente-Celis Z, Gonzalez L, Muschett D, Gonzalez F, Goldberg P. Cost-effectiveness analysis of abiraterone acetate treatment compared with cabacitaxel in Costa Rica, in patients with metastatic castration-resistant prostate cancer that have failed to chemotherapy with docetaxel. Value Health [Internet]. 2014;17:A635. https://doi.org/10.1016/j.jval.2014.08.2278.CrossRefPubMed

59.

Obando CA, Desanvicente-Celis Z, Herrera JA, Moreira M, De CJ. Cost-effectiveness analysis of ustekinumab compared with etanercept for the treatment of moderate to severe psoriasis in Costa Rica. Value Health [Internet]. 2014;17:A607. https://doi.org/10.1016/j.jval.2014.08.2120.CrossRefPubMed

60.

Elgart JF, Gonzalez L, Prestes M, Vinocour M, Solorzano J, Gagliardino JJ. Dapaglifozin versus sulfonylurea as an add-on therapy to metformin: a cost-effectiveness analysis in Costa Rica. Value Health [Internet]. Elsevier; 2016 [cited 2021 Aug 31];19:A202. http://www.valueinhealthjournal.com/article/S1098301516013644/abstract.

61.

Marin Piva H, Castro Cordero J, Sabater Cabrera E. Cost-Effectiveness analysis of abiraterone in patients with metastatic, castration-resistant, prostate cancer with progression after receiving chemotherapy with docetaxel, compared with receiving only palliative support: the perspective of the Costa Rican Public Health System (Caja Costarricense De Seguro Social). Value Health [Internet]. The Professional Society for Health Economics and Outcomes Research (ISPOR); 2016 [cited 2021 Jun 3];19:A154. https://www.ispor.org/publications/journals/value-in-health/abstract/Volume-19--Issue-3/Cost-Effectiveness-Analysis-of-Abiraterone-in-Patients-with-Metastatic--Castration-Resistant--Prostate-Cancer-with-Progression-after-Receiving-Chemotherapy-with-Docetaxel--Compared-with-Receiving-only-Palliative-Support--The-Perspective-of.

62.

Peralta-Acon M, Poveda-Fernandez J. Cost effectiveness analysis apixaban in the prevention of venous thromboembolism after total hip or knee replacement in adults in Costa Rica in 2015. Value Health [Internet]. Elsevier; 2016 [cited 2021 Aug 30];19:A48. http://www.valueinhealthjournal.com/article/S1098301516001844/abstract.

63.

Xirinachs Y. Cost-effective analysis of the dengue vaccine in Costa Rica. Value Health [Internet]. The Professional Society for Health Economics and Outcomes Research; 2016 [cited 2021 Jun 3];19:A414–5. https://www.ispor.org/publications/journals/value-in-health/abstract/Volume-19--Issue-7/Cost-Effective-Analysis-Of-The-Dengue-Vaccine-In-Costa-Rica.

64.

Castro Cordero JA, Marin Piva H, Ching Fung SM. Economical impact of treatment with omalizumab in Costa Rican social security. Value Health [Internet]. The Professional Society for Health Economics and Outcomes Research (ISPOR); 2017 [cited 2021 Jun 4];20:A201–2. https://regroup-production.s3.amazonaws.com/documents/ReviewReference/327068313/%233524%20-%20CastroCordero%202017.pdf?AWSAccessKeyId=AKIAJBZQODCMKJA4H7DA&Expires=1630381720&Signature=mt0eXatBSl6A0qSjmvJ5WOLZEQQ%3D.

65.

Castro Cordero JA, Marin Piva H, Ching Fung SM. Fulvestrant: A treatment option in metastatic breast cancer after two lines of hormonal therapy, the experience in Costa Rica. Value Health [Internet]. The Professional Society for Health Economics and Outcomes Research (ISPOR); 2017 [cited 2021 Jun 4];20:A91. https://regroup-production.s3.amazonaws.com/documents/ReviewReference/327068312/%233523%20-%20CastroCordero%202017.pdf?AWSAccessKeyId=AKIAJBZQODCMKJA4H7DA&Expires=1630381915&Signature=%2FKBjCACCsFvEUlbsaFCmvWPMN4M%3D.

66.

Lacey MJ, Brouillette M, Lenhart G, Hernández Matamoros H, Quesada Chaves DF, Bonilla Sinibaldi F, et al. Cost-effectiveness of SAC ubitril/valsartan in the treatment of heart failure in Costa Rica. Value Health [Internet]. The Professional Society for Health Economics and Outcomes Research (ISPOR); 2018 [cited 2021 Jun 4];21:S60. https://regroup-production.s3.amazonaws.com/documents/ReviewReference/327065266/%232181%20-%20Lacey%202018.pdf?AWSAccessKeyId=AKIAJBZQODCMKJA4H7DA&Expires=1630382139&Signature=Ri%2FsZmT%2B6uB2t96YDZ2v9eQb4bQ%3D.

67.

Castro Cordero JA, Ching Fung SM, Marín Piva H. [Impact of the change of presentation of the trastuzumab for the Social Security of Costa Rica, cost minimization study]. Acta Médica Costarricense [Internet]. San Jose; 2019 [cited 2021 Jun 4];61:31–6. https://regroup-production.s3.amazonaws.com/documents/ReviewReference/327068314/%233525%20-%20CastroCordero%202019.pdf?AWSAccessKeyId=AKIAJBZQODCMKJA4H7DA&Expires=1630382343&Signature=NYKD3VoFBFFPe7oJZBFWXbAqkoM%3D.

68.

Herrera LGJ, Herrera MC, González AG. [Economic Evaluation of Palivizumab Treatment in Premature Infants in the Social Security of Costa Rica, 2013-2017]. Revista Cubana de Farmacia [Internet]. 2020 [cited 2021 Jun 5];53:1–23. https://regroup-production.s3.amazonaws.com/documents/ReviewReference/327066044/%232505%20-%20Herrera%202020.pdf?AWSAccessKeyId=AKIAJBZQODCMKJA4H7DA&Expires=1630382905&Signature=Nvbbqd%2BFymWsArhHEO4mgVTPTrU%3D.

69.

Molina Hernández JP, Solorzano J, Murtiera S, Perichon S, Cercone J, Leon A. Olaparib cost-effectiveness as a maintenance treatment option for newly diagnosed BRCA-mutated ovarian cancer who are in response after first-line platinum-based chemotherapy in Costa Rica. Value Health [Internet]. The Professional Society for Health Economics and Outcomes Research (ISPOR); 2020 [cited 2021 Jun 5];23:S40. https://regroup-production.s3.amazonaws.com/documents/ReviewReference/327064164/%231721%20-%20MolinaHern%C3%A1ndez%202020.pdf?AWSAccessKeyId=AKIAJBZQODCMKJA4H7DA&Expires=1630382605&Signature=1RebVYl0qtT7zYjVxE7VYUST9qA%3D.

70.

Dueñas MDL, Lutz M, Morales G, Strutton DR, Roberts C, Cuesta G, et al. Cost-effectiveness analysis of anti-pneumococcal vaccines versus no vaccination in El Salvador. Value Health [Internet]. Elsevier; 2011 [cited 2021 Aug 31];14:A559. http://www.valueinhealthjournal.com/article/S1098301511032220/abstract.

71.

Lutz MA, Lovato P, Morales G, Cuesta G. Cost-utility analysis of varenicline vs existing smoking cessation strategies in El Salvador. Value Health [Internet]. Elsevier; 2011 [cited 2021 Aug 31];14:A496. http://www.valueinhealthjournal.com/article/S1098301511029974/abstract.

72.

Lutz MA, Zelaya R, Bogantes JP, Cuesta G. Cost-effectiveness analysis of etanercept versus available anti-Tnf And Il-6 blockers for treating rheumatoid arthritis in El Salvador. Value Health [Internet]. Elsevier; 2013 [cited 2021 Aug 31];16:A224. http://www.valueinhealthjournal.com/article/S1098301513012096/abstract.

73.

Campos NG, Maza M, Alfaro K, Gage JC, Castle PE, Felix JC, et al. The comparative and cost-effectiveness of HPV-based cervical cancer screening algorithms in El Salvador. Int J Cancer [Internet]. 2015;137:893–902. https://doi.org/10.1002/ijc.29438.CrossRefPubMed

74.

Fuentes-Alabi S, Bhakta N, Vasquez RF, Gupta S, Horton SE. The cost and cost-effectiveness of childhood cancer treatment in El Salvador, Central America: a report from the Childhood Cancer 2030 Network. Cancer [Internet]. 2018;124:391–7. https://doi.org/10.1002/cncr.31022.CrossRefPubMed

75.

Fuentes-Alabi S, Vasquez RF, Bhakta N, Rodriguez-Galindo C, Frazier AL, Atun R, et al. Cost and cost-effectiveness of childhood cancer treatment in El Salvador: a collaborative budget model. JGO [Internet]. 2017;3:19s–19s. https://doi.org/10.1200/JGO.2017.009191.CrossRef

76.

Campos NG, Maza M, Alfaro K, Gage JC, Castle PE, Felix JC, et al. The cost-effectiveness of implementing HPV testing for cervical cancer screening in El Salvador. Int J Gynaecol Obstet [Internet]. 2019;145:40–6. https://doi.org/10.1002/ijgo.12773.CrossRefPubMed

77.

Rendon AM, Oranges C, Yen G, Pavelyev A, Monsanto H, Parellada C. Public health and economic impact of a human papillomavirus vaccination program for females aged 9 years in El Salvador. Value Health Reg Issues [Internet]. 2019;19:S42.CrossRef

78.

Campos NG, Alfaro K, Maza M, Sy S, Melendez M, Masch R, et al. The cost-effectiveness of human papillomavirus self-collection among cervical cancer screening non-attenders in El Salvador. Prev Med [Internet]. 2020;131:105931. https://doi.org/10.1016/j.ypmed.2019.105931.CrossRefPubMed

79.

Lutz M, Cuesta G, Morales G. Cost-Effectiveness analysis of etanercept versus available anti-Tnf and Il-6 blockers for treating rheumatoid arthritis in Guatemala. Value Health [Internet]. Elsevier; 2011 [cited 2021 Aug 31];14:A562–3. http://www.valueinhealthjournal.com/article/S1098301511032414/abstract.

80.

Lutz MA, Grazioso C, Morales G, Strutton DR, Roberts CS, Farkouh RA, et al. Cost-effectiveness analysis of anti-pneumococcal vaccines in Guatemala. Value Health [Internet]. Elsevier; 2011 [cited 2021 Aug 31];14:A277. http://www.valueinhealthjournal.com/article/S1098301511018122/abstract.

81.

Lutz MA, Lopez R, Bogantes JP, Cuesta G. Economic evaluation of linezolid versus vancomycin for ventilator-associated pneumonia patients in Guatemala. Value Health [Internet]. Elsevier; 2013 [cited 2021 Aug 31];16:A235. http://www.valueinhealthjournal.com/article/S1098301513012655/abstract.

82.

Lutz MA, Gordillo DI, Bogantes JP, Cuesta G. Economic evaluation of apixaban for venous thromboembolism in total knee and total hip replacement in Guatemala. Value Health [Internet]. Elsevier; 2013 [cited 2021 Aug 31];16:A288. http://www.valueinhealthjournal.com/article/S1098301513015672/abstract.

83.

Obando CA, Gonzalez L, Muschett D. The Cost-Effectiveness and Cost-Utility of Paliperidone Palmitate in the Treatment of Schizophrenia in Guatemala. Value Health [Internet]. Elsevier; 2013 [cited 2021 Aug 31];16:A695. http://www.valueinhealthjournal.com/article/S1098301513040011/abstract.

84.

Davis MC, Than KD, Garton HJ. Cost effectiveness of a short-term pediatric neurosurgical brigade to Guatemala. World Neurosurg [Internet]. 2014;82:974–9. https://doi.org/10.1016/j.wneu.2014.08.038.CrossRefPubMed

85.

Garita M, Peralta M, Gordillo DI. Cost Effectiveness Of Apixaban, Dabigatran rivaroxaban and warfarin for atrial fibrillation in Guatemala. Value Health [Internet]. Elsevier; 2014 [cited 2021 Aug 31];17:A115. http://www.valueinhealthjournal.com/article/S1098301514007220/abstract.

86.

Garita-Aguilar M, Peralta-Acon M, Chavez-Perez N. Cost effectiveness of tofacitinib as second line treatment vs using biological therapies in the treatment of moderate rheumatoid arthritis after failure of DMARDs in Guatemala in 2014. Value Health [Internet]. Elsevier; 2015 [cited 2021 Aug 31];18:A163. http://www.valueinhealthjournal.com/article/S1098301515010001/abstract.

87.

Garita-Aguilar M, Peralta-Acon M, Jiménez-Crespo L. Cost effectiveness analysis of apixaban compared to oral anticoagulants in the prevention of thromboembolic events in patients with non-valvular atrial fibrillation in Guatemala in 2014. Value Health [Internet]. Elsevier; 2015 [cited 2021 Aug 31];18:A142. http://www.valueinhealthjournal.com/article/S1098301515008827/abstract.

88.

Rodriguez BC, Leal S, Calvimontes G, Hutton D. Cost-effectiveness of radiofrequency ablation for supraventricular tachycardia in Guatemala: patient outcomes and economic analysis from a low-middle-income country. Value Health Reg Issues [Internet]. 2015;8:92–8. https://doi.org/10.1016/j.vhri.2015.06.002.CrossRefPubMedPubMedCentral

89.

Agulnik A, Antillon-Klussmann F, Soberanis Vasquez DJ, Arango R, Moran E, Lopez V, et al. Cost-benefit analysis of implementing a pediatric early warning system at a pediatric oncology hospital in a low-middle income country. Cancer [Internet]. 2019;125:4052–8. https://doi.org/10.1002/cncr.32436.CrossRefPubMed

90.

Constenla D, Rivera M, Rheingans RD, Antil L, Vasquez ML. [Economic evaluation of an evuentual incorporation of anti-rotavirus vaccinne into childhood immunization program in Honduras]. Rev Med Hondur [Internet]. 2006;74:19–29. https://regroup-production.s3.amazonaws.com/documents/ReviewReference/327067734/%233287%20-%20Constenla%202006.pdf?AWSAccessKeyId=AKIAJBZQODCMKJA4H7DA&Expires=1630431085&Signature=fKhdZ5EsenwYDtpnTrvFQ7GDHAI%3D.

91.

Perkins RB, Langrish SM, Stern LJ, Burgess JF, Simon CJ. Impact of patient adherence and test performance on the cost-effectiveness of cervical cancer screening in developing countries: the case of Honduras. Womens Health Issues [Internet]. 2010;20:35–42. https://doi.org/10.1016/j.whi.2009.09.001.CrossRefPubMed

92.

Lutz MA, Alvarado T, Bogantes JP, Cuesta G. A Cost-Effectiveness Analysis Of Linezolid Versus Vancomycin For Ventilator-Associated Pneumonia Patients In Honduras. Value Health [Internet]. Elsevier; 2013 [cited 2021 Aug 31];16:A234. http://www.valueinhealthjournal.com/article/S1098301513012606/abstract.

93.

Lutz MA, Alonzo H, Bogantes JP, Cuesta G. Cost-effectiveness analysis of etanercept versus available anti-TNF and IL-6 blockers for treating rheumatoid arthritis in Honduras. Value Health [Internet]. The Professional Society for Health Economics and Outcomes Research (ISPOR); 2013 [cited 2021 Jun 6];16:A224. https://regroup-production.s3.amazonaws.com/documents/ReviewReference/327065538/%232350%20-%20Lutz%202013.pdf?AWSAccessKeyId=AKIAJBZQODCMKJA4H7DA&Expires=1630431638&Signature=BA03aO1mcuxwzCSRxVd3%2BS%2FhZbQ%3D.

94.

Tadisina KK, Chopra K, Tangredi J, Thomson JG, Singh DP. Helping hands: a cost-effectiveness study of a humanitarian hand surgery mission. Plast Surg Int [Internet]. 2014;2014:921625. https://doi.org/10.1155/2014/921625.CrossRefPubMedPubMedCentral

95.

Aguilar IBM, Mendoza LO, García O, Díaz I, Figueroa J, Duarte RM, et al. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras. Vaccine [Internet]. 2015;33(Suppl 1):A167–73. https://doi.org/10.1016/j.vaccine.2014.12.067.CrossRefPubMed

96.

Eblovi D, Antúnez M, Clitheroe K, Meeks M, Balmert L, Thornton H, et al. Effectiveness, cost-effectiveness, and economic impact of a multi-specialty charitable surgical center in Honduras. Int J Surg Open [Internet]. 2019;20:7–14.CrossRef

97.

Fullerton JT, Frick KD, Fogarty LA, Fishel JD, Vivio DM. Active management of third stage of labour saves facility costs in Guatemala and Zambia. J Health Popul Nutr. 2006;24:540–51.PubMedPubMedCentral

98.

Rheingans RD, Constenla D, Antil L, Innis BL, Breuer T. Potential cost-effectiveness of vaccination for rotavirus gastroenteritis in eight Latin American and Caribbean countries. Rev Panam Salud Publica [Internet]. 2007;21:205–16. https://doi.org/10.1590/s1020-49892007000300003.CrossRefPubMed

99.

Goldie SJ, Diaz M, Constenla D, Alvis N, Andrus JK, Kim S-Y. Mathematical models of cervical cancer prevention in Latin America and the Caribbean. Vaccine [Internet]. 2008;26(Suppl 11):L59-72. https://doi.org/10.1016/j.vaccine.2008.05.063.CrossRefPubMed

100.

Shepard DS, Suaya JA. Cost-effectiveness of a dengue vaccine in Southeast Asia and Panama: preliminary estimates. In: Preedy VR, Watson RR, editors. Handbook of disease burdens and quality of life measures [Internet]. New York: Springer New York; 2010. p. 1281–96. https://doi.org/10.1007/978-0-387-78665-0_73.

101.

Carrasco LR, Lee VJ, Chen MI, Matchar DB, Thompson JP, Cook AR. Strategies for antiviral stockpiling for future influenza pandemics: a global epidemic-economic perspective. J R Soc Interface [Internet]. 2011;8:1307–13. https://doi.org/10.1098/rsif.2010.0715.CrossRefPubMedPubMedCentral

102.

Lutz MA, Lovato P, Cuesta G. Cost-effectiveness analysis of varenicline versus existing smoking cessation strategies in Central America and the Caribbean using the BENESCO model. Hosp Pract [Internet]. 2012;40:24–34. https://doi.org/10.3810/hp.2012.02.945.CrossRef

103.

Alarid-Escudero F, Sosa-Rubí SG, Fernández B, Galárraga O. Cost-benefit analysis: HIV/AIDS prevention in migrants in Central America. Salud Publica Mex [Internet]. 2013;55(Suppl 1):S23-30.CrossRefPubMedPubMedCentral

104.

Mould-Quevedo J. Economic Outcomes For Celecoxib In Latin America: A Cost-Effectiveness Study Of Cox-2 Inhibitors Against Nsaids+Ppi For Adult Patients With Osteoarthritis And Rheumatoid Arthritis In Brazil, Mexico, Colombia, Argentina And Costa Rica. Value Health [Internet]. Elsevier; 2013 [cited 2021 Aug 30];16:A221. http://www.valueinhealthjournal.com/article/S1098301513011923/abstract.

105.

Niëns LM, Zelle SG, Gutiérrez-Delgado C, Rivera Peña G, Hidalgo Balarezo BR, Rodriguez Steller E, et al. Cost-effectiveness of breast cancer control strategies in Central America: the cases of Costa Rica and Mexico. PLoS One [Internet]. 2014;9:e95836. https://doi.org/10.1371/journal.pone.0095836.

106.

Campos NG, Tsu V, Jeronimo J, Mvundura M, Lee K, Kim JJ. When and how often to screen for cervical cancer in three low- and middle-income countries: a cost-effectiveness analysis. Papillomavirus Res [Internet]. 2015;1:38–58.CrossRefPubMedCentral

107.

Constenla DO. Post-introduction economic evaluation of pneumococcal conjugate vaccination in Ecuador, Honduras, and Paraguay. Rev Panam Salud Publica [Internet]. 2015;38:388–95.PubMed

108.

Gaziano T, Abrahams-Gessel S, Surka S, Sy S, Pandya A, Denman CA, et al. Cardiovascular disease screening by community health workers can be cost-effective in low-resource countries. Health Aff [Internet]. 2015;34:1538–45. https://doi.org/10.1377/hlthaff.2015.0349.CrossRefPubMedCentral

109.

Kuznik A, Muhumuza C, Komakech H, Marques EMR, Lamorde M. Antenatal syphilis screening using point-of-care testing in low- and middle-income countries in Asia and Latin America: a cost-effectiveness analysis. PLoS One [Internet]. 2015;10:e0127379. https://doi.org/10.1371/journal.pone.0127379.CrossRefPubMed

110.

Pichon-Riviere A, Glujovsky D, Garay OU, Augustovski F, Ciapponi A, Serpa M, et al. Oxytocin in uniject disposable auto-disable injection system versus standard use for the prevention of postpartum hemorrhage in latin america and the caribbean: a cost-effectiveness analysis. PLoS One [Internet]. 2015;10:e0129044. https://doi.org/10.1371/journal.pone.0129044.CrossRefPubMed

111.

Elgart JF, Prestes M, Gonzalez L, Solorzano J, Gagliardino JJ. Cost-effectiveness of type 2 diabetes (T2DM) treatment with dapagliflozin as add-on to metformin in the Dominican Republic and Guatemala. Value Health [Internet]. Elsevier; 2016 [cited 2021 Aug 31];19:A671–2. http://www.valueinhealthjournal.com/article/S1098301516332363/abstract.

112.

Emmett SD, Tucci DL, Bento RF, Garcia JM, Juman S, Chiossone-Kerdel JA, et al. Moving beyond GDP: cost effectiveness of cochlear implantation and deaf education in Latin America. Otol Neurotol [Internet]. 2016;37:1040–8. https://doi.org/10.1097/MAO.0000000000001148.

113.

Zeng W, Halasa-Rappel YA, Baurin N, Coudeville L, Shepard DS. Cost-effectiveness of dengue vaccination in ten endemic countries. Vaccine [Internet]. 2018;36:413–20. https://doi.org/10.1016/j.vaccine.2017.11.064.CrossRefPubMed

114.

Campos NG, Tsu V, Jeronimo J, Mvundura M, Kim JJ. Estimating the value of point-of-care HPV testing in three low- and middle-income countries: a modeling study. BMC Cancer [Internet]. 2017;17:791. https://doi.org/10.1186/s12885-017-3786-3.CrossRefPubMedPubMedCentral

115.

Campos NG, Jeronimo J, Tsu V, Castle PE, Mvundura M, Kim JJ. The cost-effectiveness of visual triage of human papillomavirus-positive women in three low- and middle-income countries. Cancer Epidemiol Biomarkers Prev [Internet]. 2017;26:1500–10. https://doi.org/10.1158/1055-9965.EPI-16-0787.CrossRefPubMed

116.

Heckert J, Richter S, Iruhiriye E, Leroy J, Olney D, Ruel M. Cost and cost-effectiveness of food-assisted maternal and child health and nutrition programs in Burundi and Guatemala. In: Carrera M, Gil A, Martínez JA, editors. IUNS 21st International Congress of Nutrition. Annals of Nutrition and Metabolism; 2017. p. 719.

117.

Correia MITD, Perman MI, Pradelli L, Omaralsaleh AJ, Waitzberg DL. Economic burden of hospital malnutrition and the cost-benefit of supplemental parenteral nutrition in critically ill patients in Latin America. J Med Econ [Internet]. 2018;21:1047–56. https://doi.org/10.1080/13696998.2018.1500371.CrossRefPubMed

118.

Pasricha S-R, Gheorghe A, Ashour F, Arcot A, Murray-Kolb LE, Suchdev P, et al. Risk-benefit and cost-effectiveness of universal iron interventions for public health control of anemia in young children in 78 countries: A microsimulation study. Blood [Internet]. American Society of Hematology; 2018;132:2276–2276. https://ashpublications.org/blood/article/132/Supplement%201/2276/261771/RiskBenefit-and-CostEffectiveness-of-Universal.

119.

Scott N, Palmer A, Morgan C, Lesi O, Spearman CW, Sonderup M, et al. Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study. Lancet Glob Health [Internet]. 2018;6:e659–67. https://doi.org/10.1016/S2214-109X(18)30219-5.CrossRefPubMed

120.

Bartsch SM, Asti L, Cox SN, Durham DP, Randall S, Hotez PJ, et al. What is the value of different zika vaccination strategies to prevent and mitigate zika outbreaks? J Infect Dis [Internet]. 2019;220:920–31. https://doi.org/10.1093/infdis/jiy688.CrossRefPubMed

121.

Pasricha S-R, Gheorghe A, Sakr-Ashour F, Arcot A, Neufeld L, Murray-Kolb LE, et al. Net benefit and cost-effectiveness of universal iron-containing multiple micronutrient powders for young children in 78 countries: a microsimulation study. Lancet Glob Health [Internet]. 2020;8:e1071–80. https://doi.org/10.1016/S2214-109X(20)30240-0.CrossRefPubMedPubMedCentral

122.

Tschampl CA, Undurraga EA, Ledogar RJ, Coloma J, Legorreta-Soberanis J, Paredes-Solís S, et al. Cost-effectiveness of community mobilization (Camino Verde) for dengue prevention in Nicaragua and Mexico: a cluster randomized controlled trial. Int J Infect Dis [Internet]. 2020;94:59–67. https://doi.org/10.1016/j.ijid.2020.03.026.CrossRefPubMed

123.

Borghi J, Gorter A, Sandiford P, Segura Z. The cost-effectiveness of a competitive voucher scheme to reduce sexually transmitted infections in high-risk groups in Nicaragua. Health Policy Plan [Internet]. 2005;20:222–31. https://doi.org/10.1093/heapol/czi026.CrossRefPubMed

124.

Broughton EI, Gomez I, Nuñez O, Wong Y. Cost-effectiveness of improving pediatric hospital care in Nicaragua. Rev Panam Salud Publica [Internet]. 2011;30:453–60.PubMed

125.

Broughton EI, López SR, Aguilar MN, Somarriba MM, Pérez M, Sánchez N. Economic analysis of a pediatric ventilator-associated pneumonia prevention initiative in nicaragua. Int J Pediatr [Internet]. 2012;2012:359430. https://doi.org/10.1155/2012/359430.CrossRefPubMedPubMedCentral

126.

Lutz MA, Lovato P, Cuesta G. Cost analysis of varenicline versus bupropion, nicotine replacement therapy, and unaided cessation in Nicaragua. Hosp Pract [Internet]. 2012;40:35–43. https://doi.org/10.3810/hp.2012.02.946.CrossRef

127.

Broughton EI, Gomez I, Sanchez N, Vindell C. The cost-savings of implementing kangaroo mother care in Nicaragua. Rev Panam Salud Publica [Internet]. 2013;34:176–82.PubMed

128.

Lopez Boo F, Palloni G, Urzua S. Cost-benefit analysis of a micronutrient supplementation and early childhood stimulation program in Nicaragua. Ann N Y Acad Sci [Internet]. 2014;1308:139–48. https://doi.org/10.1111/nyas.12368.CrossRef

129.

Broughton E, Nunez D, Moreno I. Cost-effectiveness of improving health care to people with HIV in Nicaragua. Nurs Res Pract [Internet]. 2014;2014:232046. https://doi.org/10.1155/2014/232046.CrossRefPubMedPubMedCentral

130.

Saunders JE, Barrs DM, Gong W, Wilson BS, Mojica K, Tucci DL. Cost effectiveness of childhood cochlear implantation and deaf education in Nicaragua: a disability adjusted life year model. Otol Neurotol. 2015;36:1349–56.CrossRefPubMed

131.

Broughton EI, Nunez O, Arana R, Oviedo A. Effectiveness and efficiency of improving HIV service provision for key populations in Nicaragua. Front Public Health [Internet]. 2016;4:249. https://doi.org/10.3389/fpubh.2016.00249.CrossRefPubMedPubMedCentral

132.

Campos NG, Mvundura M, Jeronimo J, Holme F, Vodicka E, Kim JJ. Cost-effectiveness of HPV-based cervical cancer screening in the public health system in Nicaragua. BMJ Open [Internet]. 2017;7:e015048. https://doi.org/10.1136/bmjopen-2016-015048.CrossRefPubMedPubMedCentral

133.

Wong L-Y, Espinoza F, Alvarez KM, Molter D, Saunders JE. Otoacoustic emissions in rural Nicaragua: cost analysis and implications for newborn hearing screening. Otolaryngol Head Neck Surg [Internet]. 2017;156:877–85. https://doi.org/10.1177/0194599817696306.CrossRefPubMed

134.

Constenla D, Ortega-Barría E, Rheingans RD, Antil L, Sáez-Llorens X. [Economic impact of rotavirus vaccination in Panama]. An Pediatr [Internet]. 2008;68:128–35. https://doi.org/10.1157/13116227.

135.

Standaert B, Gomez J, Acosta-Rodriguez C, Debrus S. Do we adequately model the benefit of Rotavirus vaccination over time? Value Health [Internet]. 2010;13:A444.CrossRef

136.

Lutz MA, Villalobos D, Morales G, Cuesta G. A cost-effectiveness analysis of linezolid versus vancomycin for ventilator-associated pneumonia patients in Panama. Value Health [Internet]. Elsevier; 2011 [cited 2021 Aug 31];14:A274. http://www.valueinhealthjournal.com/article/S1098301511017992/abstract.

137.

Lutz M, Lovato P, Penna M, Cuesta G. Cost-Utility of Varenicline versus Interventions Available for Quitting Smoking in Panama Using the BENESCO Model. Value Health [Internet]. Elsevier; 2011 [cited 2021 Aug 31];14:A140. http://www.valueinhealthjournal.com/article/S1098301511009193/abstract.

138.

Lutz MA, Trujillo JM, Morales G, Cuesta G. A cost-effectiveness analysis of voriconazol, anfotericine b and caspofungin for invasive aspergilosis patients in Panama. Value Health. The Professional Society for Health Economics and Outcomes Research (ISPOR); 2011;14:A276.

139.

Desanvicente-Celis Z, Obando CA, Rodriguez E, Gonzalez L, Muschett D. Cost-Effectiveness Analysis of Bendamustine-Rituximab Treatment Compared with Fludarabine-Rituximab Treatment, in Patients with Indolent Non-Hodgkin’s Lymphoma in Panamá. Value Health [Internet]. Elsevier; 2014 [cited 2021 Aug 30];17:A83. http://www.valueinhealthjournal.com/article/S109830151400535X/abstract.

140.

Obando CA, Desanvicente-Celis Z, Gonzalez L, Muschett D, Gonzalez F, Goldberg P. Cost-effectiveness analysis of abiraterone acetate treatment compared with cabacitaxel in the Republic of Panama, in patients with metastatic castration-resistant prostate cancer that have failed to chemotherapy with docetaxel. Value Health [Internet]. 2014;17:A632. https://doi.org/10.1016/j.jval.2014.08.2261.CrossRefPubMed

141.

Garita-Aguilar M, Peralta-Acon M, Gorriz-Añorbes L. Cost effectiveness of tofacitinib as second line treatment vs using biological therapies in the treatment of moderate rheumatoid arthritis after failure of DMARDs in Panama in 2014. Value Health [Internet]. Elsevier; 2015 [cited 2021 Aug 31];18:A162. http://www.valueinhealthjournal.com/article/S1098301515009961/abstract.

142.

Jenkins L, Nordio J, Vasarhelyi K, Nunez A, Barrios R, Rutherford A. A mathematical model to determine potential costs and benefits of increasing antiretroviral therapy coverage in female sex workers: the case of Panama. J Int AIDS Soc [Internet]. 2015. https://doi.org/10.7448/IAS.18.5.20339.

143.

Garcia LN, Cerezo L, Blas A, Alvarez S, Quiroz N, Navas AGC, et al. Cost of dengue and cost-effectiveness of the dengue vaccine in Panama. Value Health [Internet]. Elsevier; 2016 [cited 2021 Aug 31];19:A414. http://www.valueinhealthjournal.com/article/S1098301516317570/abstract.

144.

Castillo-Fernandez O, Murtiera S, Solorzano J, Martin C, Amador Sosa JL, Lim Law M, et al. Cost-effectiveness of olaparib as a maintenance treatment option for newly diagnosed BRCA-mutated ovarian cancer who are in response after first-line platinum-based chemotherapy in Panama. Value Health [Internet]. Elsevier; 2020 [cited 2021 Aug 31];23:S38. http://www.valueinhealthjournal.com/article/S1098301520318118/abstract.

145.

Torres Toala FG, Solorzano J, Baldi J, Landaverde D, González I. Budget impact analysis for olaparib maintenance therapy for brca-mutated platinum sensitive recurrent ovarian cancer in Costa Rica. Value Health [Internet]. 2018;21:S21.CrossRef

146.

Chaverri J, Castro J. Economic Impact of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus No Vaccination in Adults >60 Years, in Costa Rican Social Security. Value Health [Internet]. Elsevier; 2020 [cited 2021 Aug 31];23:S171. http://www.valueinhealthjournal.com/article/S109830152030680X/abstract.

147.

Peralta-Acon M, Chavez-Perez N. Budget impact analysis of tofacitinib in the treatment of moderate rheumatoid arthritis after failure of DMARDs in Guatemala in 2015. Value Health [Internet]. Elsevier; 2016 [cited 2021 Aug 31];19:A229. http://www.valueinhealthjournal.com/article/S109830151601192X/abstract.

148.

Fiedler JL, Villalobos CA, De Mattos AC. An activity-based cost analysis of the Honduras community-based, integrated child care (AIN-C) programme. Health Policy Plan [Internet]. 2008;23:408–27. https://doi.org/10.1093/heapol/czn018.

149.

Garita M, Peralta M, Lopez RI. Budget impact analysis of crizotinib as treatment of anaplastic lymphoma kinase (ALK) positive advanced NSCLC in Panama. Value Health. 2014;17:A75.CrossRef

150.

Torres Toala FG, Solorzano J, Baldi J, Castillo-Fernandez O. Budget impact for olaparib maintenance therapy for brca-mutated platinum sensitive recurrent ovarian cancer in panama. Value Health [Internet]. 2018;21:S22.

151.

Moreno Velásquez I, Tribaldos Causadias M, Valdés R, Gómez B, Motta J, Cuero C, et al. End-stage renal disease-financial costs and years of life lost in Panama: a cost-analysis study. BMJ Open [Internet]. 2019;9:e027229. https://doi.org/10.1136/bmjopen-2018-027229.CrossRefPubMedPubMedCentral

152.

Chen AT, Pedtke A, Kobs JK, Edwards GS Jr, Coughlin RR, Gosselin RA. Volunteer orthopedic surgical trips in Nicaragua: a cost-effectiveness evaluation. World J Surg [Internet]. 2012;36:2802–8. https://doi.org/10.1007/s00268-012-1702-1.CrossRefPubMed

153.

Mogyorosy Z, Smith P. The main methodological issues in costing health care services: A literature review [Internet]. Centre for Health Economics, University of York; 2005. Report No.: 007cherp. https://ideas.repec.org/p/chy/respap/7cherp.html.

154.

World Health Organization. Commission on Macroeconomics and Health. Macroeconomics and Health: Investing in Health for Economic Development : Report of the Commission on Macroeconomics and Health : Executive Summary [Internet]. World Health Organization; 2001. https://play.google.com/store/books/details?id=W5o6SwAACAAJ.

155.

Newall AT, Jit M, Hutubessy R. Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines. Pharmacoeconomics [Internet]. 2014;32:525–31. https://doi.org/10.1007/s40273-014-0162-x.CrossRefPubMed

156.

Marseille E, Larson B, Kazi DS, Kahn JG, Rosen S. Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull World Health Organ [Internet]. 2015;93:118–24. https://doi.org/10.2471/BLT.14.138206.CrossRefPubMed

157.

Bertram MY, Lauer JA, De Joncheere K, Edejer T, Hutubessy R, Kieny M-P, et al. Cost-effectiveness thresholds: pros and cons. Bull World Health Organ [Internet]. 2016;94:925–30. https://doi.org/10.2471/BLT.15.164418.CrossRefPubMedPubMedCentral

158.

Leech AA, Kim DD, Cohen JT, Neumann PJ. Use and misuse of cost-effectiveness analysis thresholds in low- and middle-income countries: trends in cost-per-DALY studies. Value Health [Internet]. 2018;21:759–61. https://doi.org/10.1016/j.jval.2017.12.016.CrossRefPubMedPubMedCentral

159.

Soto Molina H, Marquez-Cruz M, Pardo Gutiérrez I, Rodríguez Mendoza M, Martínez JPD. A systematic review of health economic evaluations in Mexico. Value Health [Internet]. Elsevier; 2018 [cited 2022 Jan 8];21:S215–6. http://www.valueinhealthjournal.com/article/S1098301518317686/abstract.

160.

Navadhi Market Research. Global Pharmaceuticals Industry Analysis and Trends 2023 [Internet]. Navadhi; 2019. https://www.marketresearchreports.com/navadhi/global-pharmaceuticals-industry-analysis-and-trends-2023.

161.

Augustovski F, García Martí S, Espinoza MA, Palacios A, Husereau D, Pichon-Riviere A. Estándares consolidados de reporte de evaluaciones económicas sanitarias: adaptación al español de la lista de comprobación CHEERS 2022. Value Health Reg Issues [Internet]. 2022;27:110–4. https://doi.org/10.1016/j.vhri.2021.11.001.CrossRefPubMed

162.

Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. BMJ [Internet]. 2013;346:f1049. https://doi.org/10.1136/bmj.f1049.CrossRefPubMed

163.

Dmytraczenko T, Almeida G. Toward universal health coverage and equity in Latin America and the Caribbean: evidence from selected countries [Internet]. World Bank Publications; 2015. https://play.google.com/store/books/details?id=dcADCgAAQBAJ.

164.

Bommer C, Sagalova V, Heesemann E, Manne-Goehler J, Atun R, Bärnighausen T, et al. Global Economic burden of diabetes in adults: projections from 2015 to 2030. Diabetes Care [Internet]. 2018;41:963–70. https://doi.org/10.2337/dc17-1962.

165.

Wang V, Vilme H, Maciejewski ML, Boulware LE. The economic burden of chronic kidney disease and end-stage renal disease. Semin Nephrol [Internet]. 2016;36:319–30. https://doi.org/10.1016/j.semnephrol.2016.05.008.CrossRefPubMed

166.

Couser WG, Remuzzi G, Mendis S, Tonelli M. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int [Internet]. 2011;80:1258–70. https://doi.org/10.1038/ki.2011.368.CrossRefPubMed

167.

Trautmann S, Rehm J, Wittchen H-U. The economic costs of mental disorders: do our societies react appropriately to the burden of mental disorders? EMBO Rep [Internet]. 2016;17:1245–9. https://doi.org/10.15252/embr.201642951.CrossRefPubMedPubMedCentral

168.

The Lancet Global Health. Mental health matters. Lancet Glob Health [Internet]. 2020;8:e1352. https://doi.org/10.1016/S2214-109X(20)30432-0

169.

Hopewell S, Loudon K, Clarke MJ, Oxman AD, Dickersin K. Publication bias in clinical trials due to statistical significance or direction of trial results. Cochrane Database Syst Rev [Internet]. 2009. https://doi.org/10.1002/14651858.MR000006.pub3.CrossRefPubMed

Title: A Systematic Review of Health Economic Evaluations and Budget Impact Analyses to Inform Healthcare Decision-Making in Central America
Authors: Carlos Rojas-Roque
Alfredo Palacios
Publication date: 31-01-2023
Publisher: Springer International Publishing
Published in: Applied Health Economics and Health Policy / Issue 3/2023
Print ISSN: 1175-5652
Electronic ISSN: 1179-1896
DOI: https://doi.org/10.1007/s40258-023-00791-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

A Systematic Review of Health Economic Evaluations and Budget Impact Analyses to Inform Healthcare Decision-Making in Central America

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2023

Discrete Choice Experiments in Health State Valuation: A Systematic Review of Progress and New Trends

An Investigation into the Relationship Between Choice of Model Structure and How to Adjust for Subsequent Therapies Using a Case Study in Oncology

Cost Effectiveness of Denosumab for Secondary Prevention of Osteoporotic Fractures Among Postmenopausal Women in China: An Individual-Level Simulation Analysis

Global Pull Incentives for Better Antibacterials: The UK Leads the Way

Economic Evaluation of Evusheld for Preexposure Prevention of COVID-19 in High-Risk Populations: Early Evidence from Thailand

Medication Adherence and Healthcare Costs in Chronically Ill Patients Using German Claims Data